학술논문
Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study
Document Type
Article
Author
Source
In The Lancet Oncology January 2020 21(1):95-104
Subject
Language
ISSN
1470-2045